{"id":3762,"date":"2021-05-17T20:21:14","date_gmt":"2021-05-17T11:21:14","guid":{"rendered":"https:\/\/www.emukk.com\/WP\/?p=3718"},"modified":"2021-05-17T20:25:53","modified_gmt":"2021-05-17T11:25:53","slug":"a-unique-glycosylation-pattern-in-relapse-prone-breast-cancer-comparing-with-non-relapsed-cancer-tja-ii-binding-%ce%b2-galnac","status":"publish","type":"post","link":"https:\/\/www.emukk.com\/WP\/en\/a-unique-glycosylation-pattern-in-relapse-prone-breast-cancer-comparing-with-non-relapsed-cancer-tja-ii-binding-%ce%b2-galnac\/","title":{"rendered":"A unique glycosylation pattern in relapse-prone breast cancer comparing with non-relapsed cancer\u00a0: TJA-II binding \u03b2-GalNAc"},"content":{"rendered":"

A group from Juntendo University School of Medicine, etc. has found a unique glycosylation pattern in relapse-prone breast cancer comparing with non-relapsed cancer with using lectin microarrays.
\nhttps:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0250747<\/a><\/p>\n

Breast cancer is one of the most common malignant tumors among women. Triple-negative breast cancer (TNBC) is a relapse-prone breast cancer subset that accounts for about 15\u201320% of all breast cancers and is defined by tumors lacking estrogen receptor expression, progesterone receptor expression, and increased expression of human epidermal growth factor receptor-2 (HER2). An adjuvant therapy, cytotoxic chemotherapy is the only available treatment option for TNBC patients, because they do not respond to hormone or anti-HER2 treatment.<\/p>\n

Authors found that TJA-II, which has binding specificity to Fuc\u03b11-2Gal and\/or \u03b2-GalNAc glycans, shows higher intensity in cell extracts from surgical specimens of relapsed TNBC patients than in non-relapsed patients, and histochemical TJA-II staining of adjacent sections confirmed this difference. Since two more lectins, WFA and BLP, showed similar tendency to TJA-II, some glycoproteins having \u03b2-linked terminal GalNAc are to be in the background of this finding. The next stage is definitely to find out new target molecules for the effective therapy of the relapse-prone TNBC subset.<\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A group from Juntendo University School of Medicine, etc. has found a unique glycosylation pattern in relapse-<\/p><\/div>\n

\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70],"tags":[],"class_list":["post-3762","post","type-post","status-publish","format-standard","hentry","category-nature-en"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t